US data intelligence company CorEvitas acquires pregnancy platform Pregistry

The US data intelligence company CorEvitas has announced the acquisition of the pregnancy platform Pregistry.

Pregistry aims to leverage the expertise of pregnancy specialists covering a range of clinical, safety, regulatory, marketing, and technology needs to provide information that supports healthy pregnancies and births.

The platform partners with global pharmaceutical and biotechnology companies to conduct observational studies on drug and vaccine safety during pregnancy.

Its data, the developers say, informs individuals, providers, and industry stakeholders regarding health and safety during and after pregnancy, ensuring that prescribers, regulators, and pharmaceutical companies have enough information to understand the potential benefits and risks of medications and vaccines during pregnancy.

By acquiring Pregistry, CorEvitas, a data intelligence company which creates and manages patient registries to study therapies, aims to expand its evidence footprint to include syndicated pregnancy observational studies and retrospective claims studies.

“For the last eight years, Pregistry has been a leader in the design and execution of pregnancy exposure registries to fulfil global regulatory commitments, such as mandates from the FDA and the EMA, and other observational studies in the maternal health field, including the world’s largest pregnancy registries on COVID-19 vaccines and COVID-19 treatments,” said Dr Diego Wyszynski, founder and CEO of Pregistry.

“Now, with CorEvitas’ investment and partnership, our teams will be able to provide deeper clinical registry data, a holistic view of the pregnant person’s experience, and deeper resources to our customers.

“Pregnant people and healthcare providers will have access to more information, allowing better treatment decisions and healthier pregnancies and babies.”

Raymond H. Hill, chairman of the board and CEO of CorEvitas, said: “We are excited to partner with Dr Wyszynski and his team as we embark together on the next stage of expansion into syndicated pregnancy registries and leverage our companies’ collective resources, novel technology platforms, and deep patient insights to better serve our pharmaceutical customers.”

The terms of the deal were not disclosed.